Percutaneous Management of Upper Urinary Tract Transitional Cell Carcinoma

Jonathan J. Rhee, Thomas W. Jarrett

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Upper urinary tract transitional cell carcinoma (UTTCC) of the upper urinary tract is rare. The nephroureterectomy with bladder-cuff excision has been the "gold standard" to treat UTTCC. However, a certain cohort of the population will require alternative treatment options due to comorbidities. Percutaneous treatment has become one feasible approach to treat UTTCC. Results have been acceptable when compared to the gold standard therapy, nephroureterectomy with bladder-cuff excision. However, the efficacy of intracavitary Bacillus Calmette-Guérin (BCG) therapy has been conflicting. Randomized trial is necessary to assess the efficacy of intracavitary BCG treatment for UTTCC.

Original languageEnglish (US)
Title of host publicationSmith's Textbook of Endourology
Subtitle of host publication3rd Edition
PublisherWiley-Blackwell
Pages316-325
Number of pages10
Volume1
ISBN (Print)1444335545, 9781444335545
DOIs
StatePublished - Jan 5 2012
Externally publishedYes

Keywords

  • BCG
  • Bladder-cuff excision
  • Endoscopic treatment
  • Laser ablation
  • Nephroureterectomy
  • Percutaneous access
  • Percutaneous treatment
  • Renal pelvis
  • Tumor resection
  • Upper urinary tract transitional cell carcinoma
  • Ureter

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Percutaneous Management of Upper Urinary Tract Transitional Cell Carcinoma'. Together they form a unique fingerprint.

Cite this